Table 4.
The relationship between the expression of STEAP2 and clinicopathological features of NSCLC patients
Pathological features | N | STEAP2 | χ2 | P | |
---|---|---|---|---|---|
High expression | Low expression | ||||
n (%) | n (%) | ||||
Age | 0.198 | 0.656 | |||
≤60 | 130 | 23 (17.7) | 107 (82.3) | ||
>60 | 128 | 20 (15.6) | 108 (84.4) | ||
Sex | 0.030 | 0.864 | |||
Male | 159 | 27 (17.0) | 132 (83.0) | ||
Female | 99 | 16 (16.2) | 83 (83.8) | ||
TNM clinical stages | 19.379 | 0.000 | |||
I and II stages | 108 | 31 (28.7) | 77 (71.3) | ||
III and IV stages | 150 | 12 (8.0) | 138 (92.0) | ||
Histological type | 0.230※ | 0.891※ | |||
Squamous carcinoma | 121 | 20 (16.5) | 101 (83.5) | 9.408# | 0.009# |
I grade | 32 | 13 (40.6) | 19 (59.4) | ||
II grade | 48 | 13 (27.1) | 35 (72.9) | ||
III grade | 41 | 4 (9.8) | 37 (90.2) | ||
Adenocarcinoma | 112 | 18 (16.1) | 94 (83.9) | 14.298* | 0.006* |
Lepidic-predominant | 25 | 12 (48.0) | 13 (52.0) | ||
Acinar-predominant | 21 | 9 (42.9) | 12 (57.1) | ||
Papillary-predominant | 19 | 6 (31.6) | 13 (68.4) | ||
Solid-predominant | 24 | 3 (12.5) | 21 (87.5) | ||
Micropapillary-predominant | 23 | 2 (8.7) | 21(91.3) | ||
Adenosquamous carcinoma | 25 | 5 (20.0) | 20 (80.0) | ||
Lymphatic metastasis | 35.352 | 0.000 | |||
N0 | 95 | 33 (34.7) | 62 (65.3) | ||
N+ | 163 | 10 (6.1) | 153 (93.9) |
※There was no statistical significance in the high expression rate of STEAP2 in different pathological types of NSCLC, such as squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma (P > 0.05). #There was statistical significance in the high expression rate of STEAP2 in different histological grades of squamous cell carcinoma, when the histological grade increased, the high expression rate of STEAP2 decreased (P < 0.05). *There was statistical significance in the high expression rate of STEAP2 in different pathological subtypes of adenocarcinoma; the high expression rate of STEAP2 in well-differentiated lepidic adenocarcinoma was significantly higher than that in poorly differentiated solid and micropapillary adenocarcinoma (P < 0.05)